Placebo-controlled, relapse prevention trials in schizophrenia may be unnecessary


In a viewpoint published in JAMA Psychiatry , experts from Columbia University wrote that placebo-controlled, relapse prevention studies for schizophrenia should no longer be conducted; instead, trials should use active comparators that would protect patients from relapse and offer data on the comparative effectiveness of the drugs involved.{f33f8214-8db8-4c1c-96bd-7d9e20be3d00}/placebo-controlled-relapse-prevention-trials-in-schizophrenia-may-be-unnecessary?utm_medium=social&utm_source=twitter&utm_campaign=sociallinks